New clotting drug may cut bleeding risk in rare cancer surgery

This study tests whether a concentrated clotting drug (fibrinogen) can better control major blood loss during surgery for pseudomyxoma peritonei, a rare abdominal cancer. About 90 adults will be randomly assigned to receive either the drug or a standard blood product during their operation. The goal is to see if the drug reduces the need for blood transfusions and improves surgical outcomes.